LCLi-Chien Chang

Li-Chien Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li-Chien Chang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • An-Rong Lee

    School of Pharmacy, National Defense Medical Center, Taipei City, Taiwan, Republic of China

    1 shared publication
  • Chao-Wen Cheng

    Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan

    1 shared publication
  • Chung-Hsien Lee

    Taiwan Product Quality Research Institute, Taipei City, Taiwan, Republic of China

    1 shared publication
  • Chung-Ze Wu

    Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110301, Taiwan

    1 shared publication
  • Hsiao-Feng Lee

    Taiwan Product Quality Research Institute, Taipei City, Taiwan, Republic of China

    1 shared publication
  • Jin-Shuen Chen

    Department of Administration, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

    1 shared publication

Latest Publications

  • Open Access

    Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs

    by Yu-Ching Chang, Chung-Ze Wu, Chao-Wen Cheng, Jin-Shuen Chen, Li-Chien Chang

    During tumorigenesis, urokinase (uPA) and uPA receptor (uPAR) play essential roles in mediating pathological progression in many cancers. To understand the crosstalk between the uPA/uPAR signaling and cancer, as well as to decipher their cellular pathways, we proposed to use cancer driver genes to map out the uPAR signaling. In the study, an integrated pharmaceutical bioinformatics approach that combined modulator identification, driver gene ontology networking, protein targets prediction and networking, pathway analysis and uPAR modulator screening platform construction was employed to uncover druggable targets in uPAR signaling for developing a novel anti-cancer modality. Through these works, we found that uPAR signaling interacted with 10 of 21 KEGG cancer pathways, indicating the important role of uPAR in mediating intracellular cancerous signaling. Furthermore, we verified that receptor tyrosine kinases (RTKs) and ribosomal S6 kinases (RSKs) could serve as signal hubs to relay uPAR-mediated cellular functions on cancer hallmarks such as angiogenesis, proliferation, migration and metastasis. Moreover, we established an in silico virtual screening platform and a uPAR–driver gene pair rule for identifying potential uPAR modulators to combat cancer. Altogether, our results not only elucidated the complex networking between uPAR modulation and cancer but also provided a paved way for developing new chemical entities and/or re-positioning clinically used drugs against cancer.


  • Open Access

    A substructure-based screening approach to uncover N-nitrosamines in drug substances

    by Yu-Ting Kao, Shu-Fen Wang, Meng-Hsiu Wu, Shwu-Huey Her, Yi-Hsuan Yang, Chung-Hsien Lee, Hsiao-Feng Lee, An-Rong Lee, Li-Chien Chang, Li-Heng Pao

    Drug substances are at risk of contamination with N-nitrosamines (NAs), well-known carcinogenic agents, during synthesis processes and/or long-term storage. Therefore, in this study, we developed an efficient data-based screening approach to systemically assess marketed products and investigated its scalability for benefiting both regulatory agencies and pharmaceutical industries. A substructure-based screening method employing DataWarrior, an open-source software, was established to evaluate the risks of NA impurities in drug substances. Eight NA substructures containing susceptible amino sources for N-nitrosation have been identified as screening targets: dimethylamine (DMA), diethylamine, isopropylethylamine, diisopropylamine, N-methyl-2-pyrrolidone, dibutylamine, methylphenylamine, and tetrazoles. Our method detected 192 drug substances with a theoretical possibility of NA impurity, 141 of which had not been reported previously. In addition, the DMA moiety was significantly dominant among the eight NA substructures. The results were validated using data from the literature, and a high detection sensitivity of 0.944 was demonstrated. Furthermore, our approach has the advantage of scalability, owing to which 31 additional drugs with suspected NA-contaminated substructures were identified using the substructures of 1-methyl-4-piperazine in rifampin and 1-cyclopentyl-4-piperazine in rifapentine. In conclusion, the reported substructure-based approach provides an effective and scalable method for the screening and investigation of NA impurities in various pharmaceuticals and might be used as an ancillary technique in the field of pharmaceutical quality control for risk assessments of potential NA impurities.